Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Moclobemide--placebo-controlled trials

T Silverstone1

  • 1Department of Psychological Medicine, St Bartholomew's Hospital, London, UK.

International Clinical Psychopharmacology
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drugs and driving.

British journal of clinical pharmacology·2012
Same author

Menstrual cycle effects on the action of buspirone on food intake in healthy female volunteers.

Journal of psychopharmacology (Oxford, England)·2012
Same author

A double-blind placebo-controlled study of rolipram in depressed in-patients.

Journal of psychopharmacology (Oxford, England)·2012
Same author

Neurochemical and psychoanalytical approaches to mania.

Proceedings of the Royal Society of Medicine·2010
Same author

Sumatriptan challenge in bipolar patients with and without migraine: a neuroendocrine study of 5-HT1D receptor function.

International clinical psychopharmacology·2002
Same author

Serotonin and bipolar disorder.

Journal of affective disorders·2001
Same journal

Critical reassessment of manic and psychotic episodes related to levetiracetam: a systematic review of published case reports.

International clinical psychopharmacology·2026
Same journal

Expanding the horizon of brexpiprazole augmentation in treatment-resistant disorders: from obsessive-compulsive disorder to adolescent bipolar disorder.

International clinical psychopharmacology·2026
Same journal

Acceptability-adjusted speed in psychotic agitation: interpreting pro re nata antipsychotic data in real-world care (commentary on Hatta et al.).

International clinical psychopharmacology·2026
Same journal

Antipsychotics in clinical practice: agitation, polypharmacy, and treatment resistance.

International clinical psychopharmacology·2026
Same journal

Methylphenidate treatment in adults with comorbid attention-deficit/hyperactivity disorder and borderline personality disorder: a prospective longitudinal study.

International clinical psychopharmacology·2026
Same journal

Association between anxious depression and clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD).

International clinical psychopharmacology·2026
See all related articles

Moclobemide, a novel antidepressant, demonstrated significant efficacy compared to placebo and was well-tolerated in clinical trials. Its effectiveness was comparable to established tricyclic antidepressants, offering a potentially improved treatment option.

Area of Science:

  • Pharmacology
  • Clinical Trials
  • Psychiatry

Background:

  • Moclobemide is a reversible inhibitor of monoamine oxidase A (RIMA).
  • Tricyclic antidepressants (TCAs) are standard treatments for depression.
  • Assessing moclobemide's efficacy and tolerability against placebo and TCAs is crucial.

Purpose of the Study:

  • To review placebo-controlled and three-way comparison trials of moclobemide.
  • To evaluate moclobemide's efficacy and tolerability relative to placebo and TCAs.
  • To determine moclobemide's potential as an antidepressant treatment.

Main Methods:

  • Review of three placebo-controlled trials.
  • Review of four three-way comparison trials (moclobemide, placebo, TCA).
  • Comparison of patient improvement rates and adverse event profiles.

Related Experiment Videos

Main Results:

  • Moclobemide showed significantly greater improvement than placebo in placebo-controlled trials.
  • Two three-way trials indicated moclobemide efficacy was superior to placebo and similar to TCAs (imipramine, amitriptyline).
  • Moclobemide exhibited better tolerability than TCAs.

Conclusions:

  • Moclobemide is an effective antidepressant with a favorable safety profile.
  • Moclobemide demonstrates comparable efficacy to established TCAs.
  • Moclobemide represents a viable alternative antidepressant treatment.